Melinda Telli, MD
Medical Oncology · Stanford, CANPI 1932135290
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $112,776 of the $137,248 with a category attached, or 82.2%. It is spread thinly across 21 manufacturers, the largest accounting for just 19.3%. Reporting peaked in 2019 at $42,511 and has fallen 60.0% since, to $17,001 in 2025.
Across 170 payments — averaging $807.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$26K
- AstraZeneca$20K
- Bristol Myers Squibb$16K
- Eli Lilly$11K
- Genentech USA, Inc.$10K
- Daiichi Sankyo Inc.$8K
- plus $46K from 15 others
Across 753 payments — averaging $13,526 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.4M
- Hoffmann-la Roche Limited$3.2M
- Merck$1.5M
- Genentech, Inc.$936K
- Biontech SE$404K
- Bayer$368K
- plus $444K from 10 others
What the payments were for
- Consulting fees$112,77682%
- Speaking & faculty fees$7,9326%
- Grants$2500%
- Travel & lodging$10,5228%
- Food & beverage$5,5564%
- Education$350%
- Gifts$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 24 | $26,424 |
| AstraZeneca | 23 | $19,867 |
| Bristol Myers Squibb | 12 | $16,368 |
| Eli Lilly | 35 | $10,566 |
| Genentech USA, Inc. | 10 | $9,949 |
| Daiichi Sankyo Inc. | 5 | $7,769 |
| Genentech, Inc. | 2 | $7,534 |
| Pfizer | 15 | $7,363 |
| Gilead | 9 | $4,752 |
| Astrazeneca UK Limited | 4 | $3,636 |
| AbbVie | 11 | $3,602 |
| GSK | 2 | $3,349 |
| Sanofi | 1 | $3,270 |
| Blueprint Medicines Corporation | 3 | $3,010 |
| F. Hoffmann-la Roche AG | 1 | $2,870 |
| Novartis | 2 | $2,062 |
| Lilly USA, LLC | 1 | $1,800 |
| Stemline Therapeutics Inc. | 2 | $1,573 |
| Reflexion Medical, Inc. | 6 | $1,221 |
| G1 Therapeutics, Inc. | 1 | $182 |
| Biontech SE | 1 | $81 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$137,248 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 14 | $323 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Stanford
- Ronald LevyStanford$475K
- Mark PegramStanford$374K
- Saad Munib Ahmed KhanStanford$262K
- Sandhya SrinivasStanford$220K
- Joel NealStanford$199K
- Gabriel MannisStanford$171K
- Lipika GoyalStanford$166K
- Ranjana AdvaniStanford$113K
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.